| ●Editorial | Fukushima M | 148-9 | Full text | |
| ●LHSI - the first anniversary commemoration symposium Building a Learning Health Society to Overcome Intractable Diseases and Realize a Frailty-free Society with Implementation of Regenerative Medicine and Robotic Suit HAL in Society: Reality of Overcoming Long-term Care Needs Organized by：Learning Health Society Institute | 151-251 | Abstract | ||
| Opening remarks | Fukushima M | 155-9 | ||
| Keynote speech 1 | Arai H | 160-73 | ||
| Lecture 1 | Sotozono C | 174-85 | ||
| Lecture 2 | Dezawa M | 186-93 | ||
| Lecture 3 | Yamano Y，Matsuda F | 194-208 | ||
| Keynote speech 2 | Teramukai S | 209-19 | ||
| Lecture 4 | Nakajima T | 220-5 | ||
| Lecture 5 | Nagai Y | 226-38 | ||
| Closing remarks | Ohe K | 239-51 | ||
| ●Materials | ||||
| Objective of the document published in this issue: “Petition to the mayor of Nagoya city: The three critical proposals for extension of healthy lifespan and substantial reduction of the number of people with long-term care needs” | Fukushima M | 253 | ||
| Petition to the mayor of Nagoya city: The three critical proposals for extension of healthy lifespan and substantial reduction of the number of people with long-term care needs | Arai H，Matsuo S，Maseki M， Hattori T，Nagai Y，Fujii S， Fukushima M | 255-7 | ||
| ●Articles | ||||
| Considering the future of clinical research at the turning point of implementation of the new legislation in Japan －Consideration of regulatory approval system in Japan and ‘Emergency Approval System’ enforced by the amendment of the Pharmaceutical and Medical Device Act in 2022 due to the COVID-19 pandemic－ | Ohshima H，Aoyagi M，Tajima M， Nomura T，Kato Y，Koike R， Suzuki Y，Yamashita S，Ikeda T， Aoki H | 259-73 | Full text | |
| On the procrastination of approval determination of ensitrelvir: Consideration on the composite endpoint | Saio T | 275-80 | Full text | |
| ●Instructions for authors［Japanese］＆［English］ | 281-9 | Full text | ||
| ●Editor’s note | Kurihara C | 291 | Full text | |